We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Fitchett

David Fitchett MD

Recent Contributions to PracticeUpdate:

  1. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Independently of LDL-C and Statin Use
  2. In High Risk Patients, Canagliflozin Reduces Risk of Cardiovascular Death and Heart Failure Hospitalization
  3. Risks of Cardiovascular Events and Mortality Are Lower With Dapagliflozin Than With DPP-4 Inhibitors
  4. Cardiovascular Effects of SGLT-2 Inhibitors in Type 2 Diabetes

Most Read This Week

Recently Updated